CN118215479A - 用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉 - Google Patents

用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉 Download PDF

Info

Publication number
CN118215479A
CN118215479A CN202280074138.9A CN202280074138A CN118215479A CN 118215479 A CN118215479 A CN 118215479A CN 202280074138 A CN202280074138 A CN 202280074138A CN 118215479 A CN118215479 A CN 118215479A
Authority
CN
China
Prior art keywords
composition
use according
nitroquinoline
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074138.9A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of CN118215479A publication Critical patent/CN118215479A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280074138.9A 2021-11-19 2022-11-18 用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉 Pending CN118215479A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116743.2 2021-11-19
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (1)

Publication Number Publication Date
CN118215479A true CN118215479A (zh) 2024-06-18

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074138.9A Pending CN118215479A (zh) 2021-11-19 2022-11-18 用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
JP2024540439A (ja) 2024-10-31
CA3238805A1 (en) 2023-05-25
MX2024006105A (es) 2024-05-30
KR20240108407A (ko) 2024-07-09
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01
GB202116743D0 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
Ho et al. Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus
CN110545815B (zh) 细胞色素bc1复合物抑制剂的医药用途
Chen et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial—treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil
Li et al. Stellate ganglion block reduces inflammation and improves neurological function in diabetic rats during ischemic stroke
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
US20150258178A1 (en) Intranasal insulin administration for the prevention of anesthesia-induced tau pathology/tauopathies
BRPI0719203A2 (pt) Uso de fármacos indutores de hipotermia
Wu et al. Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats
Chen et al. Preoperative and postoperative analgesic techniques in the treatment of patients undergoing transabdominal hysterectomy: a preliminary randomized trial
CN118215479A (zh) 用于在丛状神经纤维瘤的治疗或预防中使用的硝羟喹啉
BR112020025946A2 (pt) composições bifuncionais para o tratamento de câncer
US20180042891A1 (en) Cancer Cell Apoptosis
CN117769419A (zh) 用于在皮肤神经纤维瘤的治疗中使用的硝羟喹啉
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
TWI804333B (zh) 醫藥組合物治療肺癌之用途
CN120322233A (zh) 用于在恶性周围神经鞘瘤的治疗或预防中使用的硝羟喹啉
US10314831B2 (en) RAC1 inhibitors of neurofibroma formation
KR20210096977A (ko) 다이설피람 및 시스플라틴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
KR20260026127A (ko) 대장암 또는 돌연변이성 대장암 치료를 위한 mek 억제제 및 pkl1 억제제의 병용 요법
Liao et al. Yong Qing Liao, Jia Min*, Zheng Xia Wu and Zhi Hu
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
US20120309821A1 (en) Use of epigallocatechin-3-gallate for immune regulation
Zheng et al. Isoliensinine Ameliorates Postoperative Neurocognitive Disorder in Aged Mice by Restoring Hippocampal IGF-1 Receptor Signaling and Suppressing Oxidative Stress and Neuroinflammation
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination